FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 6,000 shares of the stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $37.86, for a total transaction of $227,160.00. Following the completion of the sale, the director now owns 28,400 shares in the company, valued at $1,075,224. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Kalevi Kurkijarvi also recently made the following trade(s):
- On Monday, April 15th, Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock. The shares were sold at an average price of $48.09, for a total transaction of $192,360.00.
- On Monday, April 8th, Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock. The shares were sold at an average price of $53.03, for a total transaction of $212,120.00.
FGEN traded up $0.73 during trading hours on Monday, reaching $45.91. 515,200 shares of the stock traded hands, compared to its average volume of 772,729. The business’s fifty day moving average price is $39.36. The firm has a market cap of $3.96 billion, a P/E ratio of -44.57 and a beta of 1.85. FibroGen Inc has a fifty-two week low of $33.51 and a fifty-two week high of $68.55. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.09.
Several equities analysts recently issued reports on the stock. BidaskClub raised shares of FibroGen from a “hold” rating to a “buy” rating in a research note on Wednesday, June 19th. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 price objective on shares of FibroGen in a research note on Wednesday, May 29th. TheStreet downgraded shares of FibroGen from a “c-” rating to a “d+” rating in a research note on Friday, May 24th. Piper Jaffray Companies reissued a “positive” rating and set a $40.00 price objective (down previously from $65.00) on shares of FibroGen in a research note on Monday, May 27th. Finally, Zacks Investment Research downgraded shares of FibroGen from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $61.57.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in FGEN. Hillhouse Capital Advisors Ltd. acquired a new stake in FibroGen during the 4th quarter valued at $92,712,000. FMR LLC grew its holdings in FibroGen by 8.7% during the 4th quarter. FMR LLC now owns 9,760,216 shares of the biopharmaceutical company’s stock worth $451,702,000 after acquiring an additional 778,980 shares in the last quarter. Norges Bank acquired a new position in FibroGen during the 4th quarter worth $32,604,000. Fiera Capital Corp acquired a new position in FibroGen during the 1st quarter worth $34,161,000. Finally, Janus Henderson Group PLC grew its holdings in FibroGen by 27.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,208,759 shares of the biopharmaceutical company’s stock worth $120,046,000 after acquiring an additional 473,042 shares in the last quarter. 66.27% of the stock is owned by institutional investors and hedge funds.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.